Aza-peptide aldehydes and ketones: synthesis and evaluation as human 20S proteasome inhibitors

<p>Aza-peptide aldehydes and ketones were developed as a new class of peptidyl analogues to inhibit the human constitutive (c)20S proteasome as alternative therapeutics to treat multiple myeloma (MM).</p> <p>Eleven new aza-peptide aldehydes and ketones were designed based on their...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Thomas S. Corrigan (5430191) (author)
مؤلفون آخرون: Sarah E. Border (5681051) (author), Leilani M. Lotti Diaz (9279095) (author), Kayla Q. Kasper (9279101) (author), Abigail M. Noonchester (21725895) (author), Rasmiah Amer (21725892) (author), Kayla S. Kucway (21725898) (author), Michael Fleisher (21725901) (author), Joseph P. Fernandez (5070962) (author), Alex R. Lovins (18369796) (author), Ana K. Serrano (18148657) (author), Conor R. Caffrey (113916) (author), Anthony J. O’Donoghue (7206356) (author), Don M. Benson Jr (22444028) (author), Christopher M. Hadad (1336719) (author), Özlem Doğan Ekici (9279107) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
الوصف
الملخص:<p>Aza-peptide aldehydes and ketones were developed as a new class of peptidyl analogues to inhibit the human constitutive (c)20S proteasome as alternative therapeutics to treat multiple myeloma (MM).</p> <p>Eleven new aza-peptide aldehydes and ketones were designed based on their preference to bind at the ß5 catalytic subunit of c20S proteasome with benzyloxycarbonyl(Cbz)-Leu-Leu-Leu (MG132-like) and morpholinyl(Mp)-Homophenylalanyl(HPh)-Leu-Phe-Leu (Carfilzomib-like) sequences, synthesized, structurally characterized and evaluated for their inhibitory potency in competitive kinetic assays in vitro. Additionally, cell viability assays and molecular modeling experiments were designed and performed in support.</p> <p>Aza-peptide aldehydes and ketones generated inhibitory activity with IC<sub>50</sub> values in the µM range when tested at the ß5 catalytic subunit of the human c20S proteasome. Compound 1 was the most potent compound with an IC<sub>50</sub> value of 2.3 ± 1.5 µM. When tested for concentration-dependent killing of three multiple myeloma, one leukemic and two normal natural killer (NK) cell lines, two compounds generated mid-µM EC<sub>50</sub> values only for the cancer cells after 48 h.</p> <p>Overall, aza-peptide aldehydes and ketones are a new class of selective human c20S proteasome inhibitors with the potential for further development as alternative therapeutics for multiple myeloma.</p>